Sawai Reports ‘Solid Overall’ Full Year Results Despite Some Misses

Industry Analysts Noted Slip In The Japanese Firm’s Operating Profit

Continuing in its medium-term business plan and company reform, Sawai forecasts its revenue to exceed ¥200bn in the coming fiscal year.

Japan listed 14 drugs
Japan shifts towards more active in addressing drug gap through its policies. (Shutterstock)

More from Earnings

More from Generics Bulletin